Results 81 to 90 of about 22,889 (244)

Potential Mechanisms of Trimetazidine and Coenzyme Q10 Against Antipsychotic‐Induced Myocarditis: A Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 7, July 2026.
In this study, we explored the mechanisms for the therapeutic effects of TMZ and CoQ10 on myocarditis using network pharmacology, molecular docking, and molecular dynamics simulations. Our findings identified core targets of TMZ and CoQ10 treatment of myocarditis; the five core targets included EGFR, MMP9, PPARG, AKT1, and CASP3.
Ximing Chen, Dongyin Zhuo, Jiatong Zou, Haitao Song, Kaifang Yao, Hongjun Tian, Chuanjun Zhuo   +6 more
wiley   +1 more source

Development and Validation of an HPLC Method for Analysis of Topotecan in Human Cerebrospinal Fluid and Its Application in Elimination Evaluation of Topotecan after Intraventricular Injection

, 2021
Intrathecal administration of anticancer drugs is an effective dosage strategy, but the elimination of intraventricular drugs is not uniform in all patients.
Mariko Kinoshita, Naoki Yoshikawa, Ryuji Ikeda, Hiroshi Moritake, Tsubasa Yokota, Ai Yamada, Yusei Yamada   +6 more
core   +1 more source

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

Case Reports in Oncology, 2014
Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease.
Donato Callegaro-Filho, John J. Kavanagh, Alpa M. Nick, Pedro T. Ramirez, Kathleen M. Schmeler   +4 more
doaj   +1 more source

A living biobank of sarcoma patient‐derived cell cultures reveals multi‐omic and functional insights that capture disease heterogeneity

Clinical and Translational Medicine, Volume 16, Issue 7, July 2026.
Preclinical models for sarcoma that preserve tumour biology are urgently needed to advance mechanistic understanding and functional precision oncology. 29 early‐passage patient‐derived sarcoma cell (PDC) cultures from 19 patients, representing 11 sarcoma subtypes were established and extensively characterized.
Stefanie Gijsels, Suzanne Fischer, David Creytens, Sándor Dedeyne, Felix De Vuyst, Cláudio Pinheiro, Fleur Cordier, Sarah‐Lee Bekaert, Nadine Van Roy, Kaat Durinck, Jarne Pauwels, Kris Gevaert, Pieter Mestdagh, Jo Vandesompele, Pekka Rappu, Jyrki Heino, An Hendrix, Gabrielle H. van Ramshorst, Gwen Sys, Olivier De Wever   +19 more
wiley   +1 more source

Natural Products as Modulators of ABC Transporters in Breast Cancer

Phytotherapy Research, Volume 40, Issue 7, Page 4611-4637, July 2026.
ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan, Reyhaneh Farghadani, Ammu K. Radhakrishnan   +2 more
wiley   +1 more source

Augmenting tumor sensitivity to topotecan by transient hypoxia

, 2005
We examined how the effect of topotecan is modulated by transient hypoxia in three different tumor lines, Lewis lung carcinoma (LLC), U87 human glioblastoma and DMS273 human small cell lung cancer.
Lund, Eva L., Hansen, Lasse T., Kristjansen, Paul E.G.   +2 more
core   +1 more source

Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats

Pharmaceuticals, 2020
Topotecan is actively used in clinic, with its primary use being in treatment of various types of cancer. The approved administration routes are oral and intravenous.
Seung-Hyun Jeong, Ji-Hun Jang, Yong-Bok Lee   +2 more
doaj   +1 more source

MYCN Amplification in RB1‐Inactivated Retinoblastoma: Association With High‐Risk Features

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior.
Kyriaki Papaioannou, Regina Kubica, Karen Fischhuber, Jasmin Beygo, Madlen Reschke, Petra Ritter‐Sovinz, Eva Biewald, Petra Ketteler, Dietmar Lohmann, Deniz Kanber   +9 more
wiley   +1 more source

Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan

International Journal of Molecular Sciences, 2019
Epithelial ovarian cancer (EOC) is one of the deadliest gynecological malignancies. Topotecan remains an essential tool in second-line therapy; even so, most patients develop resistance within a short period of time.
O. Menyhárt, J. Fekete, Balázs Győrffy   +2 more
semanticscholar   +1 more source

Factors Influencing Topotecan CNS Penetration in Mouse Models

, 2008
Camptothecin analogs such as topotecan are currently tested in clinical trials for brain tumors. However the clinical outcome is far below the expectations, which are derived from the promising preclinical studies.
Shen, Jun
core   +2 more sources